Opexa Therapeutics to Present at the Lazard Capital Markets 8th Annual Healthcare Conference

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the Lazard Capital Markets 8th Annual Healthcare Conference on Wednesday, November 16, 2011, at 10:30 a.m. EST. The conference will be held at The Pierre Hotel in New York City.

A live and archived webcast of the company presentation can be accessed via the Investor Relations section of the Company’s website at www.opexatherapeutics.com.

About Opexa

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS). The Company’s lead therapy, Tovaxin®, a personalized cellular immunotherapy treatment, is in late stage clinical development for MS. Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.

For more information, please visit the Company’s website at www.opexatherapeutics.com.



CONTACT:

Neil K. Warma
Opexa Therapeutics, Inc.
President & CEO
281-775-0600
[email protected]
Investors:
Carney Noensie
Burns McClellan
212-213-0006
[email protected]

KEYWORDS:   United States  North America  New York  Texas

INDUSTRY KEYWORDS:   Health  AIDS  Biotechnology  Genetics  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.